Payment overview · 2025
General Payments
$2,123.13
123 reported records · 20 companies
Healthcare provider profile · identity verified
Christopher Scott Crooker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAWRENCEVILLE, GA · NPI 1609801018
Verified facts
What the public records show
CMS Open Payments records show Christopher Scott Crooker, M.D. received $2,123.13 in general payments during 2025 across 123 reported records.
ABBVIE INC. accounted for 14.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Ozempic, Synthroid, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $306.63 | 14.4% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $282.07 | 13.3% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $191.73 | 9.0% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $175.95 | 8.3% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $175.50 | 8.3% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $155.39 | 7.3% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $146.72 | 6.9% | 13 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $122.34 | 5.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $86.58 | 4.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $73.46 | 3.5% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $64.50 | 3.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $53.71 | 2.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.46 | 2.3% | 3 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.54 | 2.2% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.47 | 2.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $40.43 | 1.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.94 | 1.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.55 | 1.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.76 | 0.9% | 5 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.40 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,118.28 | 122 |
| Education | $4.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $249.41 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $179.51 | 10 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $155.39 | 11 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $140.22 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $137.61 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $133.75 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $127.54 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $123.27 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $122.34 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $90.74 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $89.66 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.56 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.01 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $66.85 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $64.50 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $53.71 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $51.40 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $48.13 | 5 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $47.54 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.54 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.72 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $42.04 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.90 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $40.43 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $39.94 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $32.82 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.55 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $25.76 | 2 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| EDARBYCLOR Normalized: edarbyclor |
Drug | Azurity Pharmaceuticals, Inc. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.76 | 5 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $12.22 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $12.22 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $10.60 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $4.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 198 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 64 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 103 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 301 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 193 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
193 | 51 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 18 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
99 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
107 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
301 | 59 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
198 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
47 | 47 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1644 | 475 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1528 | 472 |
| Amlodipine Besylate | Amlodipine Besylate | 1208 | 364 |
| Alprazolam | Alprazolam | 1154 | 211 |
| Omeprazole | Omeprazole | 959 | 293 |
| Losartan Potassium | Losartan Potassium | 920 | 281 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 864 | 137 |
| Lisinopril | Lisinopril | 760 | 250 |
| Gabapentin | Gabapentin | 661 | 199 |
| Metformin Hcl | Metformin Hcl | 627 | 196 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 548 | 185 |
| Trazodone Hcl | Trazodone Hcl | 535 | 162 |
| Metoprolol Succinate | Metoprolol Succinate | 528 | 160 |
| Hydrochlorothiazide | Hydrochlorothiazide | 514 | 152 |
| Zolpidem Tartrate | Zolpidem Tartrate | 493 | 109 |
| Sertraline Hcl | Sertraline Hcl | 453 | 126 |
| Pravastatin Sodium | Pravastatin Sodium | 413 | 121 |
| Tramadol Hcl | Tramadol Hcl | 412 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 393 | 131 |
| Simvastatin | Simvastatin | 393 | 114 |
| Citalopram Hbr | Citalopram Hydrobromide | 362 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 346 | 109 |
| Escitalopram Oxalate | Escitalopram Oxalate | 325 | 97 |
| Oxycodone Hcl | Oxycodone Hcl | 319 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 314 | 47 |
| Clonazepam | Clonazepam | 304 | 62 |
| Ozempic | Semaglutide | 301 | 59 |
| Metformin Hcl Er | Metformin Hcl | 292 | 85 |
| Atenolol | Atenolol | 286 | 79 |
| Glimepiride | Glimepiride | 285 | 86 |
| Lorazepam | Lorazepam | 278 | 56 |
| Meloxicam | Meloxicam | 273 | 89 |
| Montelukast Sodium | Montelukast Sodium | 271 | 80 |
| Allopurinol | Allopurinol | 264 | 79 |
| Bupropion Xl | Bupropion Hcl | 262 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 247 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 244 | 72 |
| Potassium Chloride | Potassium Chloride | 226 | 67 |
| Valsartan | Valsartan | 224 | 65 |
| Famotidine | Famotidine | 220 | 72 |
| Carvedilol | Carvedilol | 217 | 68 |
| Furosemide | Furosemide | 214 | 79 |
| Memantine Hcl | Memantine Hcl | 201 | 57 |
| Eliquis | Apixaban | 198 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 198 | 67 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 196 | 149 |
| Synthroid | Levothyroxine Sodium | 193 | 51 |
| Finasteride | Finasteride | 191 | 58 |
| Ondansetron Hcl | Ondansetron Hcl | 188 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 76 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 172 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 167 | 55 |
| Lovastatin | Lovastatin | 162 | 45 |
| Pregabalin | Pregabalin | 160 | 37 |
| Fluconazole | Fluconazole | 159 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 54 |
| Doxazosin Mesylate | Doxazosin Mesylate | 155 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 155 | 118 |
| Fluoxetine Hcl | Fluoxetine Hcl | 154 | 45 |
| Ezetimibe | Ezetimibe | 152 | 49 |
| Fenofibrate | Fenofibrate | 141 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 59 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 131 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 130 | 38 |
| Temazepam | Temazepam | 130 | 28 |
| Methylprednisolone | Methylprednisolone | 129 | 106 |
| Cefuroxime | Cefuroxime Axetil | 125 | 99 |
| Donepezil Hcl | Donepezil Hcl | 124 | 34 |
| Glipizide | Glipizide | 123 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 123 | 41 |
| Amoxicillin | Amoxicillin | 122 | 89 |
| Glipizide Er | Glipizide | 121 | 32 |
| Azithromycin | Azithromycin | 120 | 99 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 37 |
| Meclizine Hcl | Meclizine Hcl | 117 | 58 |
| Pioglitazone Hcl | Pioglitazone Hcl | 117 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 116 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 114 | 90 |
| Alendronate Sodium | Alendronate Sodium | 112 | 31 |
| Celecoxib | Celecoxib | 111 | 31 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 111 | 19 |
| Diazepam | Diazepam | 108 | 24 |
| Mounjaro | Tirzepatide | 107 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 103 | 23 |
| Jardiance | Empagliflozin | 103 | 31 |
| Sumatriptan Succinate | Sumatriptan Succinate | 103 | 22 |
| Irbesartan | Irbesartan | 101 | 26 |
| Ibuprofen | Ibuprofen | 100 | 38 |
| Januvia | Sitagliptin Phosphate | 100 | 25 |
| Myrbetriq | Mirabegron | 99 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 27 |
| Bupropion Hcl Sr | Bupropion Hcl | 95 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 92 | 26 |
| Valacyclovir | Valacyclovir Hcl | 89 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 88 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 87 | 28 |
| Ondansetron Odt | Ondansetron | 81 | 32 |
| Spironolactone | Spironolactone | 80 | 22 |
| Nifedipine Er | Nifedipine | 79 | 23 |
| Estradiol | Estradiol | 78 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 21 |
| Promethazine Hcl | Promethazine Hcl | 73 | 17 |
| Cephalexin | Cephalexin | 67 | 39 |
| Propranolol Hcl | Propranolol Hcl | 67 | 24 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 66 | 28 |
| Clonidine Hcl | Clonidine Hcl | 65 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 65 | 23 |
| Farxiga | Dapagliflozin Propanediol | 64 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 62 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 61 | 11 |
| Prednisone | Prednisone | 60 | 29 |
| Buspirone Hcl | Buspirone Hcl | 59 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 58 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 57 | 30 |
| Hydromorphone Hcl | Hydromorphone Hcl | 57 | 11 |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Modafinil | Modafinil | 56 | 16 |
| Topiramate | Topiramate | 56 | 16 |
| Mirtazapine | Mirtazapine | 54 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 53 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 21 |
| Levetiracetam | Levetiracetam | 51 | 15 |
| Terazosin Hcl | Terazosin Hcl | 50 | 15 |
| Aripiprazole | Aripiprazole | 49 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | 17 |
| Azelastine Hcl | Azelastine Hcl | 47 | 30 |
| Paxlovid | Nirmatrelvir/Ritonavir | 47 | 47 |
| Torsemide | Torsemide | 47 | 17 |
| Colchicine | Colchicine | 46 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 29 |
| Acyclovir | Acyclovir | 45 | 21 |
| Lactulose | Lactulose | 44 | 16 |
| Testosterone | Testosterone | 44 | suppressed |
| Chlorthalidone | Chlorthalidone | 42 | 14 |
| Levofloxacin | Levofloxacin | 42 | 28 |
| Xarelto | Rivaroxaban | 42 | 13 |
| Labetalol Hcl | Labetalol Hcl | 41 | 11 |
| Linzess | Linaclotide | 41 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 27 |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Lansoprazole | Lansoprazole | 40 | 15 |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 33 |
| Trulicity | Dulaglutide | 39 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Methocarbamol | Methocarbamol | 38 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | suppressed |
| Gemtesa | Vibegron | 37 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 37 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 16 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 12 |
| Doxepin Hcl | Doxepin Hcl | 33 | 12 |
| Mupirocin | Mupirocin | 33 | 21 |
| Metronidazole | Metronidazole | 32 | 24 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 31 | suppressed |
| Dutasteride | Dutasteride | 31 | suppressed |
| Cefdinir | Cefdinir | 30 | 21 |
| Colesevelam Hcl | Colesevelam Hcl | 30 | 14 |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Prolia | Denosumab | 28 | 18 |
| Sucralfate | Sucralfate | 28 | 11 |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | 23 |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Nystatin | Nystatin | 26 | 20 |
| Lidocaine | Lidocaine | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Lyrica | Pregabalin | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Triazolam | Triazolam | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Sulindac | Sulindac | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Nexium | Esomeprazole Magnesium | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Digoxin | Digoxin | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Tobramycin | Tobramycin | 15 | 14 |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Levoxyl | Levothyroxine Sodium | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,123.13 · 123 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AZMIRO, CAPLYTA, COMIRNATY, CREON, EDARBYCLOR, ELIQUIS, EVENITY, FARXIGA, Flucelvax, GEMTESA, INSPIRE, JARDIANCE, KISUNLA, KRYSTEXXA, LINZESS, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, SYNTHROID, TRELEGY ELLIPTA, TZIELD, Tlando, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error